摘要
In a recently published paper in Nature,Yamagishi et al.deliver a comprehensive exploration on the mechanistic basis and subsequent emergence of resistance of targeting histone H3 lysine trimethylation(H3K27me3)using the EZH1–EZH2 dual inhibitor,valemetostat,in adult T cell leukemia/lymphoma(ATL)patients.
基金
supported by grants from the Deutsche Krebshilfe(#70113643)
the DKTK awarded to F.D.Funding。
